Identifying patient populations vulnerable to viral infection and methods of inducing heterologous immunity in same
Assigneenference, Inc.
InventorsCOLIN PAWLOWSKI, Venkataramanan Soundararajan, Arjun Puranik, Murali Aravamudan
Life of this patent
Estimating the term…
Abstract
This application relates to methods for assessing patient populations and determining subpopulations vulnerable to viral infection, methods of reducing the risk of infection and/or inducing heterologous immunity to said viral infection.
Claims21
A method for reducing the risk of a subject acquiring or fully presenting a disease case by SARS-CoV-2 infection, comprising determining the immunization history of the subject, identifying whether the subject has not received at least one of a haemophilus influenzae type B (Hib) vaccine, a geriatric flu vaccine, a diphtheria-pertussis-tetanus vaccine, or a measles-mumps-rubella vaccine within the past 1 year, and administering at least one such vaccine to the subject.
A method for reducing the risk of a subject acquiring or fully presenting a disease case by SARS-CoV-2 infection, comprising determining the immunization history of the subject, identifying whether the subject has not received at least one of a hepatitis A/hepatitis B vaccine, a haemophilus influenzae type B (Hib) vaccine, a pneumococcal vaccine, a diphtheria-pertussis-tetanus vaccine, or a polio vaccine within the past 2 years, and administering at least one such vaccine to the subject.
A method for reducing the risk of a subject acquiring or fully presenting a disease case by SARS-CoV-2 infection, comprising determining the immunization history of the subject, identifying whether the subject has not received at least one of a polio vaccine, a pneumococcal vaccine, a geriatric flu vaccine, a varicella vaccine, an RZV zoster vaccine, or a diphtheria-pertussis-tetanus vaccine within the past 5 years, and administering at least one such vaccine to the subject.
(canceled)
A method for the identification and stratification of a subject at risk of SARS-CoV-2 infection comprising determining the immunization history of the subjects, determining the demographic covariates of the subject, and identifying whether the subject has not received at least one of a polio vaccine, a pneumococcal vaccine, a pneumococcal conjugate vaccine, a geriatric flu vaccine, a varicella vaccine, an RZV zoster vaccine, or a diphtheria-pertussis-tetanus vaccine within the past 5 years, and administering at least one such vaccine to the corresponding subject.
12-14. (canceled)
(canceled)
18-21. (canceled)
26-29. (canceled)
Dependencies are inferred from the claim text.